Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to talk about FICO stock & CPRT stock

2 extracted signals · 2 resolved · 0 still active

The Patient Investor profile imageThe Patient Investor29 Aug 2025, 22:19 UTC
Video preview for Friends! In this video, I'm going to talk about FICO stock & CPRT stock
Signals
2
Eligible signals in this source
Open
0
Still being tracked
Resolved
2
Evaluable outcomes
Successful
0
Canonical correct result
Failed
2
Canonical failed result
Resolved success
0%
Open and excluded signals omitted
Source overview

AI-generated source summary

The video analyzes FICO and CPRT, suggesting a bullish outlook for both.FICO is currently priced at $1506.37, and has a target of $2000, and is down 24.53% YTD due to market overlooking the price raising possibilities for FICO.CPRT is at $47.78, down 17.94% over six months. Target is $55, noting international expansion, growth metrics, a strong balance sheet.For FICO the analysis is invalidated if price hits $1400, and for CPRT at $40

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  4. Market predictions extracted

    2 eligible signals linked to this case.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

The Patient Investor

Tracked signals
292
Historical success
32.9%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.